Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

A Sustainable Biocatalytic Alternative for Paracetamol Production

Project description

Greener chemistry driving paracetamol production

Paracetamol is one of the most used medicines worldwide. Yet its production depends on chemical techniques that use up a lot of energy and create harmful waste. Funded by the European Research Council, the BioParacetamol project aims to develop a different approach. It plans to use enzymes to run the process at lower temperatures: this will cut down on toxic by-products while boosting productivity and scalability. With its simple one-pot, two-step method, this approach promises cleaner, more eco-friendly manufacturing. Currently in its early phases, BioParacetamol plans to grow through careful testing and a study on business potential. Successful results could put Europe at the forefront of green chemistry.

Objective

Current paracetamol production relies on century-old chemical methods that have significant environmental drawbacks, including high energy consumption, low process efficiency, and substantial waste generation. The BioParacetamol solution offers a more sustainable alternative by using enzymes to catalyse reactions at lower temperatures, producing fewer toxic by-products.
This innovative process utilises a simplified one-pot, two-step synthesis, reducing energy demands, increasing efficiency, and minimising waste, particularly harmful by-products. Designed to be both scalable and commercially viable, BioParacetamol presents a major opportunity for the pharmaceutical industry to adopt greener chemistry practices.
The BioParacetamol innovation is still in the early stages of development, with a technology readiness level (TRL) of 2, but aims to reach higher TRLs through rigorous testing and optimisation.
The project’s primary goal is to demonstrate the feasibility of this process at an industrial scale, alongside a comprehensive business feasibility study to evaluate its commercial potential. BioParacetamol represents a high-risk, high-gain opportunity with the potential to not only improve the environmental footprint of paracetamol production but also position Europe as a leader in sustainable pharmaceutical manufacturing.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-POC

See all projects funded under this call

Host institution

TECHNISCHE UNIVERSITEIT DELFT
Net EU contribution
€ 150 000,00
Total cost
No data

Beneficiaries (1)